KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial.

Nat Commun · 2026-Mar-14 · PMID 41826281

Panel B提取失败待 EXE 对齐验证

Progression-free Survival

Fig. 2. Progression-free survival by bevacizumab use. Kaplan–Meier estimate in subgroups with bevacizumab use ( A ) and without bevacizumab use ( B ), and subgroup analysis ( C ). Source data are provided as a Source data file.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分0.00
质量通过否
预期曲线2
实际曲线0
X 范围0 – 36
Y 范围0 – 100
No curves extracted

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0failed待验证02026-07-24T15:28:06+00:00